Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals, Inc. at the 2018 Cantor Global Healthcare Conference  (Replay)
    Wednesday, October 03, 2018 11:30 am EDT
Toggle Summary Spring Bank Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
MILFORD, Mass., Jan. 28, 2015 — Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RNA viruses, today announced that Douglas J. Jensen, President and CEO, will present at the 17(th) annual BIO CEO & Investor
Toggle Summary Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens
MILFORD, Mass. – September 18, 2014 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RNA viruses, today announced a research collaboration with the National Institutes of Health (NIH) for animal testing of the
Toggle Summary Spring Bank Pharmaceuticals Presents at the Nucleic Acid Summit 2014
MILFORD, Mass. – June 23, 2014   Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced two presentations at the Nucleic Acid
Toggle Summary Spring Bank Pharmaceuticals Announces Oral and Poster Presentations at the 27th International Conference on Antiviral Research
MILFORD, Mass. – May 12, 2014 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead
Toggle Summary Spring Bank Pharmaceuticals SB9200 Listed as Scientific Success Story
NIH – National Institute of Allergy and Infectious Diseases lists Spring Bank Pharmaceuticals SB9200 as one of their scientific success stories. To read full story click here
Toggle Summary Veteran Biotech Executive David Arkowitz Joins Spring Bank Pharmaceuticals’ Board of Directors
Seasoned Executive Brings Extensive Track Record of Business and Financial Experience to Clinical Stage Company MILFORD, Mass., Jan. 28, 2014 /PRNewswire/ — Spring Bank Pharmaceuticals today announced that David Arkowitz has been appointed to its Board of Directors.  Mr.
Toggle Summary Spring Bank Pharmaceuticals Commences Multiple Ascending Dose (MAD) Stage of Phase 1 clinical in HCV Patients
Milford, November 26, 2013. Spring Bank Pharmaceuticals, Inc. of Milford, MA today announced the completion of the single ascending dose portion of their Ph. 1 clinical trial in healthy HCV infected patients and the start of the first cohort of the multiple ascending dose portion of the Phase 1
Toggle Summary Spring Bank Pharmaceuticals HCV drug SB 9200 has demonstrated pan genotypic antiviral activity against all HCV genotypes in the hybrid fusion assay
Milford, November 11, 2013. Spring Bank Pharmaceuticals, Inc. of Milford, MA today announced that Dr. Graham Foster from Queen Mary University of London, presented a Poster entitled “Pan-genotypic anti-HCV activity of SB9200 assessed in the ‘capture-fusion’ replication assay’ at the recently
Toggle Summary Poster entitled, ”Preclinical Studies of SB 9200 for Hepatitis Treatment” will be presented by Marci Harter of MPI Research at the upcoming American College of Toxicology’s 34th Annual Meeting
Milford, MA.  A Poster entitled, ”Preclinical Studies of SB 9200 for Hepatitis Treatment” will be presented by Marci Harter of MPI Research at the upcoming American College of Toxicology’s 34 th Annual Meeting, in San Antonio, Texas. The presentation will include IND-enabling preclinical
Toggle Summary Dr. Graham Foster to Present a Poster on Spring Bank Pharmaceuticals’ HCV Drug SB 9200 at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
MILFORD, Mass., Oct. 7, 2013 /PRNewswire/ — Dr. Graham R. Foster and his team from Queen Mary, University of London, London, United Kingdom, will be presenting a poster titled “Pangenotypic anti-HCV activity of SB 9200 assessed in the ‘Capture-fusion’ replication assay” (Abstract No.